Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to determine whether, in patients with non treated periodontitis (stage III and IV) positive to Porphyromonas gingivalis, the use of systemic antimicrobials (metronidazole versus azithromycin) as an adjunctive treatment to periodontal surgery provides clinical and microbiological benefits.
Design: randomized, parallel and triple blind clinical trial
Sample: Patients with periodontitis (stages III and IV) and positive to Porphyromonas gingivalis who potentially need periodontal surgery were recruited. 25 patients were randomized to the test group (periodontal surgery + azithromycin) and another 25 subjects to the control group (periodontal surgery + metronidazole).
Study visits:
Examiner calibration
Recruitment of patients. Screening. Data collection (clinical and microbiological variables).
Phase I.
Phase II. Surgical periodontal treatment.
Phase III. Periodontal maintenance.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| azythromycin + periodontal surgery. | Experimental | Periodontal surgery + Azithromycin (500 mg every 24 h for 3 days). |
|
| metronidazole + periodontal surgery | Active Comparator | Periodontal surgery + Metronidazole (500 mg every 8 h for 7 days). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Azithromycin | Other | azithromycin (500 mg/24h/3 days) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Probing pocket depth (PPD) | Full mouth measurement at 6 sites per tooth, with a manual periodontal probe University North Carolina 15 (UNC-15 mm) | At 6 weeks after periodontal surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Probing pocket depth (PPD) | Full mouth measurement at 6 sites per tooth, with a manual periodontal probe UNC-15 mm | At the beginning of the study, 6 weeks after scaling and root planning (Reevaluation phase I), 6 weeks after the last surgery session (Reevaluation Phase II) and during the maintenance Phase III (3, 6, 9, 12 and 48 months after periodontal surgery) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mariano Sanz | University Complutense Madrid (UCM) | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Dentistry, Univesity Complutense, Madrid | Madrid | 28040 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010518 | Periodontitis |
| D018450 | Disease Progression |
| D010510 | Periodontal Diseases |
| D010514 | Periodontal Pocket |
| ID | Term |
|---|---|
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D017963 | Azithromycin |
| D008795 | Metronidazole |
| ID | Term |
|---|---|
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D009930 |
Not provided
Not provided
Not provided
Not provided
Not provided
The subjects were randomly assigned to the treatment groups in ascending order according to a balanced distribution system through a computer generated random number design table (random block design). Randomization was balanced according to the smoking habit at the initial visit to ensure homogeneity in the treatment groups.
The method of allocation concealment selected were opaque envelopes. The research coordinator was responsible for the randomization and allocation of patients.
The 50 opaque envelopes (25 / group) were prepared.
| Metronidazole |
| Other |
metronidazole (500 mg/8h/7 days) |
|
| Gingival Recession (REC) | Full mouth measurement at 6 sites per tooth, with a manual periodontal probe UNC-15 mm | At the beginning of the study, 6 weeks after scaling and root planning (Reevaluation phase I), 6 weeks after the last surgery session (Reevaluation Phase II) and during the maintenance Phase III (3, 6, 9, 12 and 48 months after periodontal surgery) |
| Plaque index (PlI) | Full mouth measurement at 6 sites per tooth, with a manual periodontal probe UNC-15 mm | At the beginning of the study, 6 weeks after scaling and root planning (Reevaluation phase I), 6 weeks after the last surgery session (Reevaluation Phase II) and during the maintenance Phase III (3, 6, 9, 12 and 48 months after periodontal surgery) |
| Gingival index (GI) | Full mouth measurement of the bleeding on probing at 6 sites per tooth, with a manual periodontal probe UNC-15 mm | At the beginning of the study, 6 weeks after scaling and root planning (Reevaluation phase I), 6 weeks after the last surgery session (Reevaluation Phase II) and during the maintenance Phase III (3, 6, 9, 12 and 48 months after periodontal surgery) |
| Furcations | Measurement of furcations with a manual periodontal probe UNC-15 mm | At the beginning of the study, 6 weeks after scaling and root planning (Reevaluation phase I), 6 weeks after the last surgery session (Reevaluation Phase II) and during the maintenance Phase III (3, 6, 9, 12 and 48 months after periodontal surgery) |
| Clinical attachment level (CAL) | Full mouth measurement at 6 sites per tooth, with a manual periodontal probe UNC-15 mm | At the beginning of the study, 6 weeks after scaling and root planning (Reevaluation phase I), 6 weeks after the last surgery session (Reevaluation Phase II) and during the maintenance Phase III (3, 6, 9, 12 and 48 months after periodontal surgery) |
| Total bacterial counts | A microbiological sample is taken with sterilized paper points from the gingival crevicular fluid and the total bacterial counts (expressed in total colony-forming units) are analyzed by culture. | At the beginning of the study, 6 weeks after scaling and root planning (Reevaluation phase I) and during the maintenance Phase III (3, 6, 12 and 48 months after periodontal surgery) |
| Percentage of periodontal pathogens | Determination of the percentage of the following periodontal pathogens:
| At the beginning of the study, 6 weeks after scaling and root planning (Reevaluation phase I) and during the maintenance Phase III (3, 6, 12 and 48 months after periodontal surgery) |
| Counts of periodontal pathogens | Determination of the following periodontal pathogens: Porphyromonas gingivalis
| At the beginning of the study, 6 weeks after scaling and root planning (Reevaluation phase I) and during the maintenance Phase III (3, 6, 12 and 48 months after periodontal surgery) |
| Appearance of side effects after taking antibiotic | The patient was asked if he had side effects after taking antibiotic (Yes / No) | 1 week after antibiotic consumption |
| Type of adverse effect after taking antibiotic | The patient was asked to write freely on a form the type of side effect suffered | 1 week after antibiotic consumption |
| Degree of affectation | The patient was asked to categorize the degree of affectation (mild, moderate or severe) of the secondary effect of the antibiotic if it had appeared. | 1 week after antibiotic consumption |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| Organic Chemicals |
| D009593 | Nitroimidazoles |
| D009574 | Nitro Compounds |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |